JAMA journal won’t retract oxycodone paper despite author request, citing no ‘falsification’
JAMA Internal Medicine has rejected a petition by a group of clinicians calling for the journal to retract an article on oxycodone therapy for osteoarthritis. The request — which initially included two of the paper’s original authors — stems from 19-year-old court records revealing the sponsor of the study withheld evidence about opioid withdrawal that … Continue reading JAMA journal won’t…
JAMA Internal Medicine has refused a request to retract a 2000 study on oxycodone therapy for osteoarthritis, despite a group of clinicians petitioning the journal for removal. The study, published under the journal's previous name, Archives of Internal Medicine, suggested that controlled-release oxycodone was safe and effective for managing osteoarthritis pain, with rare withdrawal symptoms.
However, court records from 2007 revealed that the study's sponsor had withheld evidence about opioid withdrawal that contradicted the paper's conclusions. Purdue, the maker of OxyContin, faced a federal criminal case for concealing information about patient dependence and withdrawal during the trial. Despite this information becoming public nearly 20 years ago, JAMA Internal Medicine maintains that the study has no evidence of fabrication or falsification and has not planned to retract it.
Written by urgent.news from Retraction Watch's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
